COVID-19NCT05422898
Discussing COVID-19 Vaccines in Private Facebook Groups
A study testing Gist messages on COVID-19 vaccination and COVID-19 vaccine information in people with COVID-19, run by George Washington University at 1 site in United States.
Trial summary
As the COVID-19 pandemic persists, a sizable proportion of the U.S. population remains unvaccinated and at high risk of death and serious illness from COVID-19. Vaccine hesitancy, fueled by the proliferation of vaccine misinformation on social media, is one factor contributing to lack of vaccination. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- COVID-19
- What is being tested?
- Gist messages on COVID-19 vaccination and COVID-19 vaccine information
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 508 participants
- Where
- 1 siteUnited States
- Study dates
- 17 Jan 2022to 4 Apr 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- reside in the U.S.
- unvaccinated from COVID-19
- Use Facebook regularly (at least 1/day)
Who cannot join
- age <18 years
- do not reside in the U.S.
- vaccinated from COVID-19
- do not use Facebook regularly (at least 1/day)
Trial locations and contacts
1 site in 1 country.
United States1 site
George Washington University
Washington D.C., District of Columbia, 20052
About this study
Official title: Empathic Engagement With the COVID-19 Vaccine Hesitant in Private Facebook Groups
As the COVID-19 pandemic persists, a sizable proportion of the U.S. population remains unvaccinated and at high risk of death and serious illness from COVID-19. Vaccine hesitancy, fueled by the proliferation of vaccine misinformation on social media, is one factor contributing to lack of vaccination. Current attempts to overcome vaccine misinformation focus on correcting or debunking falsehoods. Although debunking strategies are important components to any public health campaign, communications must also address rationales for vaccine hesitancy that vary among individuals and communities, and directly address the gist of their concerns in an empathetic, non-judgmental manner. We will conduct a randomized controlled trial to test the effectiveness of empathic, relationship-building interactions relative to standard provision of information on social media to address COVID-19 vaccine hesitancy.
- Conditions
- COVID-19
- Being tested
- Gist messages on COVID-19 vaccination, COVID-19 vaccine information
- Keywords
- vaccine hesitancy, social media, health behavior
- Medical subject headings
- COVID-19, Vaccination Hesitancy, Health Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Gist messages on COVID-19 vaccinationBehavioural
Participants will receive gist-based messages on COVID-19 vaccines and have their concerns addressed by a group moderator
COVID-19 vaccine informationBehavioural
Participants will receive a link to the Facebook COVID-19 Information Center via a private Facebook Group
| Study group | Role | What they receive |
|---|---|---|
| Gist | Experimental | Gist-based messages on COVID-19 vaccination and moderated group discussions in a private Facebook group Receives: Behavioral: Gist messages on COVID-19 vaccination |
| Information | Placebo comparator | Link to Facebook COVID-19 Information Center Receives: Behavioral: COVID-19 vaccine information |
What is being measured
The primary outcome is the main question the study is designed to answer.
Engagement and satisfaction with the program
Engagement includes participation in the Facebook group; satisfaction=self-rated overall satisfaction with the program (7-point scale)
Measured: 4 weeks
Secondary outcomes (6)
Proportion of participants getting the COVID-19 vaccine
self-reported vaccination status
Measured: 4 weeks
Change in COVID-19 vaccination intention
Self-reported intention to get the COVID-19 vaccine (7-point scale)
Measured: 4 weeks
Change in intention to encourage others to get the COVID-19 vaccine
Self-reported intention to encourage others to get the COVID-19 vaccine (7-point scale)
Measured: 4 weeks
Change in COVID-19 vaccine confidence
Self-reported confidence in the COVID-19 vaccine (5-point scale)
Measured: 4 weeks
Change in general vaccine confidence
Self-reported confidence in vaccines (7-point scale)
Measured: 4 weeks
Change in vaccine hesitancy
Self-reported vaccine hesitancy (7-point scale
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jun 2022
- Study start17 Jan 2022
- Primary completion4 Apr 2022
- Study completion4 Apr 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- More trials run by George Washington UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 508 participants (actual)
Sponsor and investigators
- Lead sponsor
- George Washington University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05422898
- Sponsor's protocol ID
- NCR213861
- Status last verified
- Jun 2022
- First submitted
- 15 Jun 2022
- Last updated
- 21 Jun 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Jun 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Empathic Engagement With the COVID-19 Vaccine Hesitant in Private Facebook Groups
- ClinicalTrials.gov ID
- NCT05422898
- Acronym / sponsor ID
- NCR213861
- Conditions
- COVID-19
- Keywords
- vaccine hesitancy, social media, health behavior
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 508 participants (actual)
- Lead sponsor
- George Washington UniversityUniversity, hospital or other
- Study start
- 17 Jan 2022 (actual)
- Primary completion
- 4 Apr 2022 (actual)
- Study completion
- 4 Apr 2022 (actual)
- First posted
- 21 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
As the COVID-19 pandemic persists, a sizable proportion of the U.S. population remains unvaccinated and at high risk of death and serious illness from COVID-19. Vaccine hesitancy, fueled by the proliferation of vaccine misinformation on social media, is one factor contributing to lack of vaccination. Current attempts to overcome vaccine misinformation focus on correcting or debunking falsehoods. Although debunking strategies are important components to any public health campaign, communications must also address rationales for vaccine hesitancy that vary among individuals and communities, and directly address the gist of their concerns in an empathetic, non-judgmental manner. We will conduct a randomized controlled trial to test the effectiveness of empathic, relationship-building interactions relative to standard provision of information on social media to address COVID-19 vaccine hesitancy.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Gist | Experimental | Behavioral: Gist messages on COVID-19 vaccinationGist-based messages on COVID-19 vaccination and moderated group discussions in a private Facebook group |
| Information | Placebo comparator | Behavioral: COVID-19 vaccine informationLink to Facebook COVID-19 Information Center |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- reside in the U.S.
- unvaccinated from COVID-19
- Use Facebook regularly (at least 1/day)
Key exclusion criteria (4 listed)
- age <18 years
- do not reside in the U.S.
- vaccinated from COVID-19
- do not use Facebook regularly (at least 1/day)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Gist messages on COVID-19 vaccinationParticipants will receive gist-based messages on COVID-19 vaccines and have their concerns addressed by a group moderator | Behavioural | Gist |
| COVID-19 vaccine informationParticipants will receive a link to the Facebook COVID-19 Information Center via a private Facebook Group | Behavioural | Information |
Primary outcome
Engagement and satisfaction with the program
Time frame: 4 weeks
Engagement includes participation in the Facebook group; satisfaction=self-rated overall satisfaction with the program (7-point scale)
6 secondary outcomes
Proportion of participants getting the COVID-19 vaccine
Time frame: 4 weeks
Change in COVID-19 vaccination intention
Time frame: 4 weeks
Change in intention to encourage others to get the COVID-19 vaccine
Time frame: 4 weeks
Change in COVID-19 vaccine confidence
Time frame: 4 weeks
Change in general vaccine confidence
Time frame: 4 weeks
Change in vaccine hesitancy
Time frame: 4 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jun 2022.
- Individual participant dataSharing planned: No
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Gist messages on COVID-19 vaccination and COVID-19 vaccine information in people with COVID-19, run by George Washington University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Engagement and satisfaction with the program (time frame: 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jun 2022.